Recent clinical findings have shed light on how sensor choice influences Continuous Glucose Monitoring Accuracy. Specifically, researchers compared subcutaneously inserted sensors with implantable versions in patients with type 1 diabetes. This study evaluated how well these devices correlate with established biomarkers like HbA1c, glycated albumin, and fructosamine.

The Study Design

Scientists analyzed data from 35 patients during this clinical evaluation. Among them, 13 participants utilized the Eversense E3 implantable system. Meanwhile, 22 patients used either the Dexcom G6 or Guardian 4 subcutaneously inserted sensors. Additionally, the team measured Mean Blood Glucose (MBG) and Time in Range (TIR) to determine their relationship with retrospective glycemic markers.

Key Results: Inserted vs. Implantable Sensors

The results revealed significant differences between the two sensor types. In the Dexcom and Guardian group, MBG and TIR showed strong correlations with all biochemical markers. Specifically, researchers noted large effect sizes for HbA1c and fructosamine. In contrast, the Eversense group demonstrated no significant correlation between CGM metrics and these biomarkers. Consequently, inserted sensors may offer a more reliable reflection of mid- to long-term glucose control.

Clinical Value of Continuous Glucose Monitoring Accuracy

Clinicians must prioritize Continuous Glucose Monitoring Accuracy when managing diabetes. Because biochemical markers provide a retrospective view, they serve as a benchmark for sensor performance. If a sensor fails to align with these markers, it might complicate therapeutic adjustments. Therefore, selecting the right device is crucial for personalized treatment plans.

Improving Patient Outcomes

Moreover, these findings suggest that different sensor technologies interact uniquely with physiological parameters. While implantable sensors offer convenience, they might require further optimization to match the reliability of inserted models. Physicians should discuss these nuances with patients to ensure effective glycemic management.

Frequently Asked Questions

Why does CGM correlation with HbA1c matter?

Correlation ensures that the daily data provided by the sensor accurately reflects the patient's long-term glucose trends. High correlation gives clinicians confidence in using CGM data for long-term treatment adjustments.

Are Dexcom G6 and Guardian 4 better than Eversense E3?

This specific study found that Dexcom G6 and Guardian 4 correlate more closely with clinical biomarkers like HbA1c. However, sensor choice also depends on patient lifestyle, duration of wear, and individual preference.

What is the role of glycated albumin in diabetes management?

Glycated albumin provides a retrospective estimate of glucose control over roughly two to three weeks. It bridges the gap between daily CGM readings and the three-month average provided by HbA1c.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Medenica S et al. Real-time continuous glucose monitoring with subcutaneously inserted sensor correlates better than subcutaneously implantable sensor with glycated hemoglobin, glycated albumin and fructosamine. Minerva Endocrinol (Torino). 2026 Mar 25. doi: 10.23736/S2724-6507.26.04486-6. PMID: 41879821.

Selvin E, et al. The Interrelationships of Glycemic Control Measures: HbA1c, Glycated Albumin, Fructosamine, 1,5-Anhydroglucitrol, and Continuous Glucose Monitoring. Journal of Diabetes Science and Technology. 2011;5(6):1441-1448.

Kovatchev BP, et al. Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems. Journal of Diabetes Science and Technology. 2022.